Cancer Biology

Discussions of New Developments and Updates

Skip to content
  • Home
  • About
  • Topics
    • Statistics & Epidemiology
      • Incidence
      • Mortality
      • Prevention
      • Diet & Nutrition
    • Biology
      • Cell Cycle
      • Tumor Microenvironment
      • Angiogenesis
      • Invasion & Metastasis
      • Immortalization
      • Stem Cells
      • Heterotypic Cellular Interactions
    • Signal Transduction
      • Receptor Tyrosine Kinase Inhibitors
      • Hormone Receptors
      • Growth Receptors
    • Genetics
      • Oncogenes
      • Tumor Suppressor Genes
      • Mutations
      • Epigenetic Regulation
      • DNA Repair
    • Immunology & Immunotherapy
      • Antibodies & Conjugates
      • Checkpoint Inhibitors
      • Vaccines
      • CAR-T
    • Therapy
      • Traditional Chemotherapy
      • Hormonal
      • Surgery & Radiation
      • Rational Drug Design
      • Off-Target Effects
      • Pharmacokinetics & Pharmacodynamics
      • Resistance
  • SHU Department of Biology
Cancer Biology

Tag Archives: PSA

RNA Vaccines in Melanoma and Prostate Cancer

Vaccine strategies for cancer immunotherapy depend on the induction of dendritic cells (DC) in close proximity to T cells. This is best accomplished in lymphoid tissue. However, directing vaccines to lymphoid tissue has been quite challenging. Continue reading →

This entry was posted in active immunotherapy, Dendritic cells, Uncategorized, Vaccines and tagged adaptive immune response, and six-transmembrane epithelial antigen of the prostate 1, BioNTech, CureVac AG, dendritic cell, IFN-α, innate immune response, interferon alpha, macrophage, MAGE-A3, NY-ESO-1, prostate cancer, prostate stem cell antigen, prostate-specific antigen, prostate-specific membrane antigen, PSA, PSCA, PSMA, RNA lipoplexes, RNA vaccine, STEAP1, toll like receptor, TPTE, transmembrane phosphatase with tensin homology, tyrosinase on July 6, 2016 by Joseph Gulfo.

Liquid Biopsy from Pathway Genomics – Appropriate Uses

Liquid biopsy is the use of blood to diagnose cancer. Pathway Genomics launched its CancerIntercept test that screens for multiple cancers. Continue reading →

This entry was posted in Biomarkers, Mutations, Oncogenes, Receptor Tyrosine Kinase Inhibitors, Transcription Factors, Tumor Suppressor Genes and tagged BRAF, CTNNB1, FOC|XL2, GNAS, KRAS, mammography, NRAS, PI3KCA, positive predictive value, PSA, sensitivity, specificity, TP53 on September 23, 2015 by Joseph Gulfo.


This blog is designed to provide updates in developments in cancer biology and engage in discussions about new findings in the field.

Sponsored by the Department of Biology, Seton Hall University.

@josephgulfo

[fts_twitter twitter_name=@josephgulfo tweets_count=6 cover_photo=no stats_bar=no show_retweets=no show_replies=no]
Proudly powered by WordPress

Pin It on Pinterest